Sign inJoin waitlistJoin the waitlist

Kevin Zarrabi

Assistant Professor · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · · · · · ·

History

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Present

Fox Chase Cancer Center
2020–2022
Internal Medicine
Stony Brook Medicine
2015–2018
ST GEORGE'S UNIV SCH OF MED, ST GEORGE'S, GRENADA
2011–2015

Research

Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration
Journal of Biological Chemistry · 2011 · First of 10 authors · 161 citations
Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration
Journal of the National Cancer Institute · 2013 · 115 citations
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer
Journal of Biological Chemistry · 2008 · 92 citations

WK
Wm Kelly
8 papers
Daniel Geynisman
6 papers
William Tester
6 papers
Matthew Zibelman
5 papers
Patrick Mille
5 papers
Shenhong Wu
5 papers
SZ
Stanley Zucker
5 papers
BM
Benjamin Miron
4 papers
Costas Lallas
4 papers
Mihir Shah
4 papers
Emmanuel Antonarakis
3 papers
LG
Leonard Gomella
3 papers

Clinical trials

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
Principal investigator · Not yet recruiting · Phase 2
Thomas Jefferson University
2026–2031
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Site PI · Recruiting · Phase 1, Phase 2
GlaxoSmithKline
2026–2030
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Site PI · Recruiting · Phase 1, Phase 2
858 Therapeutics, Inc.
2024–2026